Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ACHN
- CUSIP: 00448Q20
- Web: www.achillion.com
Capitalization:- Market Cap: $576.97 million
- Outstanding Shares: 136,723,000
Average Prices:- 50 Day Moving Avg: $4.45
- 200 Day Moving Avg: $4.13
- 52 Week Range: $3.15 - $9.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -46.89
- P/E Growth: -0.38
Sales & Book Value:- Annual Revenue: $15 million
- Price / Sales: 38.46
- Book Value: $2.80 per share
- Price / Book: 1.51
Profitability:- EBIDTA: ($66,230,000.00)
- Return on Equity: -15.93%
- Return on Assets: -15.42%
Debt:- Current Ratio: 36.07%
- Quick Ratio: 36.07%
Misc:- Average Volume: 1.50 million shs.
- Beta: 1.98
- Short Ratio: 5.29
Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01. During the same quarter in the prior year, the business posted ($0.13) EPS. View Achillion Pharmaceuticals' Earnings History.
When will Achillion Pharmaceuticals make its next earnings announcement?
Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?
8 analysts have issued twelve-month price targets for Achillion Pharmaceuticals' shares. Their predictions range from $5.00 to $16.00. On average, they expect Achillion Pharmaceuticals' share price to reach $9.29 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Clinigen Group PLC (CLIN), Xencor (XNCR), Amarin Corporation PLC (AMRN), Acorda Therapeutics (ACOR), Insmed (INSM), NeuroDerm (NDRM), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX), Aclaris Therapeutics (ACRS), ZIOPHARM Oncology (ZIOP), Retrophin (RTRX), Flexion Therapeutics (FLXN), La Jolla Pharmaceutical Company (LJPC) and Epizyme (EPZM).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- David I. Scheer, Chairman of the Board
- Milind S. Deshpande Ph.D., President, Chief Executive Officer, Director
- Mary Kay Fenton CPA, Chief Financial Officer, Executive Vice President
- Joel C. Barrish Ph.D., Executive Vice President, Chief Scientific Officer
- Martha E. Manning Esq., Executive Vice President, General Counsel, Corporate Secretary
- David Apelian M.D. Ph.D., Executive Vice President, Chief Medical Officer
- Joseph Truitt, Executive Vice President, Chief Commercial Officer
- Amy Jennings, Senior Vice President - Regulatory Affairs
- Michael D. Kishbauch, Director
- Frank A. G. M. Verwiel M.D., Director
Who owns Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Creative Planning (0.11%) and Bank of Montreal Can (0.04%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo. View Institutional Ownership Trends for Achillion Pharmaceuticals.
Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Creative Planning. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.
How do I buy Achillion Pharmaceuticals stock?
Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.22.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $9.29 (120.04% upside) |
Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/18/2017 | Leerink Swann | Upgrade | Market Perform -> Outperform | $4.00 -> $6.00 | High |  |
| 4/26/2017 | Jefferies Group LLC | Reiterated Rating | Hold | | Low | |
| 4/25/2017 | Maxim Group | Lower Price Target | Buy | $8.00 -> $5.00 | High | |
| 4/24/2017 | Robert W. Baird | Boost Price Target | Outperform | $5.00 -> $10.00 | High | |
| 2/2/2017 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy | $10.00 | N/A | |
| 11/4/2016 | Chardan Capital | Upgrade | Sell -> Neutral | $5.00 | N/A | |
| 11/3/2016 | Wedbush | Reiterated Rating | Outperform | $13.00 | N/A | |
| 9/15/2016 | FBR & Co | Initiated Coverage | Outperform | $16.00 | N/A | |
| 7/7/2016 | JMP Securities | Upgrade | Market Perform -> Outperform | $13.00 | N/A | |
| 12/8/2015 | William Blair | Reiterated Rating | Outperform | $16.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ ACHN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($0.16) | | | | | N/A | |
| 5/4/2017 | Q1 2017 | ($0.16) | ($0.15) | | | View | N/A | |
| 2/23/2017 | Q4 2016 | ($0.18) | ($0.03) | | $15.00 million | View | N/A | |
| 11/3/2016 | Q3 | ($0.16) | ($0.15) | | | View | N/A | |
| 8/4/2016 | Q2 | ($0.15) | ($0.14) | | | View | N/A | |
| 5/3/2016 | Q116 | ($0.14) | ($0.13) | | | View | N/A | |
| 2/25/2016 | Q4 | $0.09 | $0.12 | $31.40 million | $31.60 million | View | N/A | |
| 11/5/2015 | Q3 | $0.09 | $0.19 | $32.62 million | $33.82 million | View | N/A | |
| 8/10/2015 | Q2 | ($0.18) | ($0.25) | | $0.71 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.22) | ($0.17) | | | View | N/A | |
| 3/5/2015 | Q414 | ($0.19) | ($0.21) | | | View | N/A | |
| 11/4/2014 | Q314 | ($0.18) | ($0.16) | | | View | N/A | |
| 8/7/2014 | Q214 | ($0.18) | ($0.16) | | | View | N/A | |
| 5/7/2014 | Q114 | ($0.17) | ($0.17) | | | View | N/A | |
| 3/7/2014 | Q413 | ($0.16) | ($0.14) | $0.01 million | | View | N/A | |
| 11/12/2013 | Q3 | ($0.20) | ($0.14) | | | View | N/A | |
| 5/7/2013 | Q113 | ($0.15) | ($0.14) | | | View | N/A | |
| 11/8/2012 | Q312 | ($0.17) | ($0.20) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)2017 EPS Consensus Estimate: ($0.71)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.17) | ($0.16) | ($0.17) |
| Q2 2017 | 3 | ($0.17) | ($0.17) | ($0.17) |
| Q3 2017 | 3 | ($0.18) | ($0.18) | ($0.18) |
| Q4 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ:ACHN)Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 71.24%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/22/2016 | Jason S Fisherman | Director | Buy | 10,000 | $3.96 | $39,600.00 | |
| 12/5/2016 | Mary Kay Fenton | CFO | Buy | 2,500 | $4.11 | $10,275.00 | |
| 12/2/2016 | Joel C Barrish | Insider | Buy | 2,500 | $4.06 | $10,150.00 | |
| 12/30/2015 | David Apelian | insider | Sell | 10,000 | $10.50 | $105,000.00 | |
| 12/28/2015 | Mary Kay Fenton | CFO | Sell | 43,500 | $10.08 | $438,480.00 | |
| 11/11/2015 | Nicole Vitullo | Director | Sell | 550,000 | $10.17 | $5,593,500.00 | |
| 9/25/2015 | Nicole Vitullo | Director | Sell | 9,310 | $8.22 | $76,528.20 | |
| 1/23/2015 | Mary Kay Fenton | CFO | Sell | 13,125 | $16.00 | $210,000.00 | |
| 1/21/2015 | Milind Deshpande | CEO | Sell | 100,000 | $15.00 | $1,500,000.00 | |
| 9/30/2014 | Ra Capital Management, Llc | Insider | Sell | 1,332,014 | $10.20 | $13,586,542.80 | |
| 9/29/2014 | Ra Capital Management, Llc | Insider | Sell | 221,014 | $10.96 | $2,422,313.44 | |
| 9/26/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,372,915 | $11.17 | $26,505,460.55 | |
| 9/25/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 497,986 | $11.05 | $5,502,745.30 | |
| 9/24/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 1,204,929 | $11.27 | $13,579,549.83 | |
| 9/23/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,595,071 | $11.29 | $29,298,351.59 | |
| 9/2/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 835,293 | $11.63 | $9,714,457.59 | |
| 8/27/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,711,352 | $11.33 | $30,719,618.16 | |
| 8/26/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,112,867 | $11.35 | $23,981,040.45 | |
| 8/25/2014 | Joseph Truitt | EVP | Sell | 25,000 | $10.82 | $270,500.00 | |
| 8/25/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 331,396 | $10.96 | $3,632,100.16 | |
| 8/18/2014 | Milind Deshpande | CEO | Sell | 216,624 | $10.00 | $2,166,240.00 | |
| 8/18/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 4,235,000 | $9.53 | $40,359,550.00 | |
| 8/15/2014 | Michael D Kishbauch | Director | Sell | 495,812 | $9.40 | $4,660,632.80 | |
| 8/13/2014 | Gary E Frashier | Director | Sell | 5,000 | $8.00 | $40,000.00 | |
| 6/20/2014 | Ra Capital Management, Llc | Insider | Sell | 880,000 | $8.40 | $7,392,000.00 | |
| 6/16/2014 | Gary E Frashier | Director | Sell | 55,000 | $8.00 | $440,000.00 | |
| 6/16/2014 | Joseph Truitt | EVP | Sell | 25,000 | $7.82 | $195,500.00 | |
| 6/16/2014 | Qvt Associates Gp Llc | Major Shareholder | Sell | 1,819,551 | $7.70 | $14,010,542.70 | |
| 6/11/2014 | Qvt Associates Gp Llc | Major Shareholder | Sell | 128,649 | $7.66 | $985,451.34 | |
| 6/10/2014 | Joseph Truitt | EVP | Sell | 50,000 | $6.02 | $301,000.00 | |
| 6/10/2014 | Michael D Kishbauch | Director | Sell | 371,937 | $7.75 | $2,882,511.75 | |
| 12/30/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 170,239 | $3.34 | $568,598.26 | |
| 12/26/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 121,205 | $3.44 | $416,945.20 | |
| 12/23/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 289,141 | $3.24 | $936,816.84 | |
| 12/19/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 222,612 | $3.09 | $687,871.08 | |
| 12/17/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 92,803 | $3.11 | $288,617.33 | |
| 11/22/2013 | Dennis Liotta | Director | Buy | 10,000 | $2.98 | $29,800.00 | |
| 11/20/2013 | Ra Capital Management, Llc | Insider | Buy | 1,110,000 | $2.55 | $2,830,500.00 | |
| 11/19/2013 | Jason Fisherman | Director | Buy | 15,000 | $2.63 | $39,450.00 | |
| 11/12/2013 | Ra Capital Management, Llc | Insider | Buy | 1,795,000 | $2.48 | $4,451,600.00 | |
| 10/31/2013 | Ra Capital Management, Llc | Insider | Buy | 1,186,007 | $2.45 | $2,905,717.15 | |
| 10/14/2013 | Ra Capital Management, Llc | Insider | Buy | 2,369,229 | $2.79 | $6,610,148.91 | |
| 10/11/2013 | Ra Capital Management, Llc | Insider | Buy | 2,448,710 | $2.56 | $6,268,697.60 | |
| 9/30/2013 | Ra Capital Management, Llc | Insider | Buy | 2,800,000 | $2.98 | $8,344,000.00 | |
| 8/14/2013 | Jason Fisherman | Director | Buy | 5,000 | $6.83 | $34,150.00 | |
| 8/12/2013 | Dennis Liotta | Director | Buy | 5,000 | $6.47 | $32,350.00 | |
| 8/9/2013 | Qvt Associates Gp Llc | major shareholder | Buy | 102,282 | $6.41 | $655,627.62 | |
| 7/11/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 401,017 | $6.46 | $2,590,569.82 | |
| 7/10/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 390,944 | $6.33 | $2,474,675.52 | |
| 7/8/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 642,509 | $6.28 | $4,034,956.52 | |
| 7/3/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 1,963,248 | $6.43 | $12,623,684.64 | |
| 7/1/2013 | Gary E Frashier | Director | Sell | 5,000 | $8.17 | $40,850.00 | |
| 6/21/2013 | Jason S Fisherman | Director | Buy | 10,000 | $7.63 | $76,300.00 | |
| 6/7/2013 | Gary E Frashier | Director | Sell | 5,000 | $8.37 | $41,850.00 | |
| 6/3/2013 | Jason S Fisherman | Director | Buy | 10,000 | $7.87 | $78,700.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Achillion Pharmaceuticals (NASDAQ:ACHN)
Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to Post -$0.16 EPS
www.americanbankingnews.com - July 24 at 10:19 PM |
 | Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock? - Nasdaq
www.nasdaq.com - July 20 at 3:27 PM |
 | Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock?
finance.yahoo.com - July 20 at 3:27 PM |
| Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 19, 2017
finance.yahoo.com - July 19 at 3:33 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 18 at 8:32 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 10:49 AM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:14 PM |
 | Achillion Pharma (ACHN) Mingjun Huang Promoted to SVP & Head ... - StreetInsider.com
www.streetinsider.com - July 10 at 8:34 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - July 8 at 2:21 PM |
 | Biotechs head higher ahead of Q2 earnings dump - Seeking Alpha
seekingalpha.com - July 5 at 3:33 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - June 28 at 6:26 PM |
| Achillion Pharmaceuticals Financials, Price Targets and Pipeline Review
finance.yahoo.com - June 22 at 1:05 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 20 at 8:34 AM |
 | Achillion to Present at the 2017 JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 16 at 3:31 PM |
| Achillion to Present at the 2017 JMP Securities Life Sciences Conference
finance.yahoo.com - June 15 at 8:27 PM |
| Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 3:21 PM |
| Achillion to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 6:18 PM |
| Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics
finance.yahoo.com - June 5 at 1:16 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Update
www.americanbankingnews.com - May 27 at 7:06 AM |
 | Biotech Stocks on Investors' Radar -- Achillion Pharma, Acorda ... - PR Newswire (press release)
www.prnewswire.com - May 26 at 3:18 PM |
| Achillion Pharmaceuticals, Inc. Forecasted to Earn FY2018 Earnings of ($0.28) Per Share (ACHN)
www.americanbankingnews.com - May 22 at 9:34 AM |
| Why Achillion Pharmaceuticals Stock Is Jumping 15% Today
finance.yahoo.com - May 18 at 3:16 PM |
| Achillion: It Can't Get Any Worse…Or Can It?
finance.yahoo.com - May 18 at 12:34 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Outperform" by Leerink Swann
www.americanbankingnews.com - May 18 at 8:10 AM |
| Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : May 11, 2017
finance.yahoo.com - May 11 at 8:28 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 10 at 1:34 PM |
| Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2017
finance.yahoo.com - May 10 at 9:37 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 9 at 7:44 AM |
| Achillion (ACHN) Reports Wider-than-Expected Loss in Q1
finance.yahoo.com - May 8 at 3:16 PM |
| Achillion Pharmaceuticals, Inc. Expected to Earn FY2019 Earnings of $0.38 Per Share (ACHN)
www.americanbankingnews.com - May 8 at 12:12 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM |
| Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
finance.yahoo.com - May 4 at 3:17 PM |
 | Achillion reports 1Q loss
marketbeat.com - May 4 at 6:27 AM |
| Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 2 at 3:21 PM |
| Achillion Pharmaceuticals (ACHN) Earning Favorable Media Coverage, Study Shows
www.americanbankingnews.com - May 2 at 7:52 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 1 at 12:02 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:30 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:21 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 29 at 1:20 AM |
| Achillion Pharmaceuticals (ACHN) Earning Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 2:04 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:22 PM |
| ETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017
finance.yahoo.com - April 26 at 5:42 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Rating Reiterated by Maxim Group
www.americanbankingnews.com - April 25 at 11:23 AM |
 | Why Achillion Pharmaceuticals Stock Sank on Monday
www.fool.com - April 25 at 9:27 AM |
| Achillion Pharmaceuticals' (ACHN) Outperform Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - April 24 at 4:42 PM |
| Achillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6 ... - StreetInsider.com
www.streetinsider.com - April 24 at 3:20 PM |
| Somewhat Positive Press Coverage Very Likely to Affect Achillion Pharmaceuticals (ACHN) Share Price
www.americanbankingnews.com - April 24 at 11:47 AM |
| Achillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
www.streetinsider.com - April 24 at 11:16 AM |
| Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
finance.yahoo.com - April 22 at 10:55 AM |
| Favorable News Coverage Very Likely to Affect Achillion Pharmaceuticals (ACHN) Share Price
www.americanbankingnews.com - April 21 at 8:17 AM |
Achillion Pharmaceuticals (ACHN) Chart for Tuesday, July, 25, 2017
